Nathan Stasko, PhD, is co-founder, President and Chief Executive Officer and a Director of Novan, Inc. Dr. Stasko has led the transformation of the Company’s nitric oxide platform from the academic benchtop to Phase 3 clinical trials and is considered a leading expert in the field of nitric oxide. He is an inventor of the core Novan technology and of more than 100 patent filings, 19 of which have issued, and has authored several peer-reviewed manuscripts pertaining to the chemical storage and controlled release of nitric oxide. Dr. Stasko has led the Company through private financings totaling more than $100 million, government grants and contracts totaling $15 million and an initial public offering of its common stock in 2016 raising $51M. He has assembled a team of highly experienced executives and skilled professionals with drug development and commercialization expertise, who share his vision to position Novan as a commercially successful leader in the dermatology market.
See Nathan live as a Speaker at CED Life Science Conference 2017